感染和接种疫苗后针对新冠病毒变异株的中和抗体
Neutralizing Antibodies Against SARS-CoV-2 Variants After Infection and Vaccination.
作者信息
Edara Venkata Viswanadh, Hudson William H, Xie Xuping, Ahmed Rafi, Suthar Mehul S
机构信息
Emory University Department of Pediatrics, Atlanta, Georgia.
Emory Vaccine Center, Atlanta, Georgia.
出版信息
JAMA. 2021 May 11;325(18):1896-1898. doi: 10.1001/jama.2021.4388.
Abstract
This study examines the neutralizing antibody response to 4 SARS-CoV-2 variants in infected and vaccinated individuals.
摘要
本研究检测了感染和接种疫苗个体对4种新冠病毒变异株的中和抗体反应。
相似文献
1
Neutralizing Antibodies Against SARS-CoV-2 Variants After Infection and Vaccination.感染和接种疫苗后针对新冠病毒变异株的中和抗体
JAMA. 2021 May 11;325(18):1896-1898. doi: 10.1001/jama.2021.4388.
2
Infection and Vaccine-Induced Neutralizing-Antibody Responses to the SARS-CoV-2 B.1.617 Variants.针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）B.1.617变体的感染及疫苗诱导的中和抗体反应
N Engl J Med. 2021 Aug 12;385(7):664-666. doi: 10.1056/NEJMc2107799. Epub 2021 Jul 7.
3
BNT162b2-Elicited Neutralization against New SARS-CoV-2 Spike Variants.BNT162b2诱导的针对新型严重急性呼吸综合征冠状病毒2刺突变异体的中和作用。
N Engl J Med. 2021 Jul 29;385(5):472-474. doi: 10.1056/NEJMc2106083. Epub 2021 May 12.
4
Study Suggests Lasting Immunity After COVID-19, With a Big Boost From Vaccination.研究表明新冠病毒感染后可产生持久免疫力，接种疫苗能大幅增强这种免疫力。
JAMA. 2021 Aug 3;326(5):376-377. doi: 10.1001/jama.2021.11717.
5
SARS-CoV-2 Antibody Response in Persons with Past Natural Infection.既往自然感染人群中新型冠状病毒2型（SARS-CoV-2）的抗体反应
N Engl J Med. 2021 Jul 1;385(1):90-92. doi: 10.1056/NEJMc2103825. Epub 2021 Apr 14.
6
SARS-CoV-2 Omicron Variant Neutralization in Serum from Vaccinated and Convalescent Persons.接种疫苗者和康复者血清中对严重急性呼吸综合征冠状病毒2奥密克戎变种的中和作用
N Engl J Med. 2022 Feb 17;386(7):698-700. doi: 10.1056/NEJMc2119236. Epub 2022 Jan 12.
7
Antibody Response and Variant Cross-Neutralization After SARS-CoV-2 Breakthrough Infection.SARS-CoV-2突破性感染后的抗体反应及变异株交叉中和作用
JAMA. 2022 Jan 11;327(2):179-181. doi: 10.1001/jama.2021.22898.
8
Plasma Neutralization of the SARS-CoV-2 Omicron Variant.新冠病毒奥密克戎变异株的血浆中和作用
N Engl J Med. 2022 Feb 10;386(6):599-601. doi: 10.1056/NEJMc2119641. Epub 2021 Dec 30.
9
Antibody Responses after a Single Dose of SARS-CoV-2 mRNA Vaccine.单剂 SARS-CoV-2 mRNA 疫苗后的抗体反应。
N Engl J Med. 2021 May 20;384(20):1959-1961. doi: 10.1056/NEJMc2102051. Epub 2021 Mar 23.
10
SARS-CoV-2 mRNA Vaccines Elicit Different Responses in Immunologically Naïve and Pre-Immune Humans.SARS-CoV-2 mRNA 疫苗在免疫原性初免和预免疫人群中引发不同的反应。
Front Immunol. 2021 Sep 27;12:728021. doi: 10.3389/fimmu.2021.728021. eCollection 2021.
引用本文的文献
1
Binding Antibodies Responses to SARS-COV-2 Infection in Hospitalized Patients and Vaccinated Subjects: A Longitudinal Prospective Observational Study.住院患者和接种疫苗者对SARS-CoV-2感染的结合抗体反应：一项纵向前瞻性观察研究。
Saudi J Med Med Sci. 2025 Jan-Mar;13(1):39-46. doi: 10.4103/sjmms.sjmms_282_24. Epub 2025 Jan 11.
2
Risk of Kawasaki Disease/Multisystem Inflammatory Syndrome Following COVID-19 Vaccination in Korean Children: A Self-Controlled Case Series Study.韩国儿童接种新冠疫苗后发生川崎病/多系统炎症综合征的风险：一项自我对照病例系列研究。
J Korean Med Sci. 2025 Jan 20;40(3):e10. doi: 10.3346/jkms.2025.40.e10.
3
Longitudinal Follow-Up of the Specific Antibody Response to SARS-CoV-2 Vaccination in Colombia.哥伦比亚对新冠病毒疫苗接种特异性抗体反应的纵向随访
J Med Virol. 2025 Jan;97(1):e70133. doi: 10.1002/jmv.70133.
4
COVID-19 mutations: An overview.新型冠状病毒肺炎突变：概述
World J Methodol. 2024 Sep 20;14(3):89761. doi: 10.5662/wjm.v14.i3.89761.
5
Mucosal adenovirus vaccine boosting elicits IgA and durably prevents XBB.1.16 infection in nonhuman primates.黏膜型腺病毒疫苗加强免疫可诱导 IgA 产生，并可持久预防非人灵长类动物感染 XBB.1.16。
Nat Immunol. 2024 Oct;25(10):1913-1927. doi: 10.1038/s41590-024-01951-5. Epub 2024 Sep 3.
6
AS03 adjuvant enhances the magnitude, persistence, and clonal breadth of memory B cell responses to a plant-based COVID-19 vaccine in humans.AS03 佐剂增强了基于植物的 COVID-19 疫苗在人体中引发的记忆 B 细胞应答的幅度、持久性和克隆广度。
Sci Immunol. 2024 Apr 5;9(94):eadi8039. doi: 10.1126/sciimmunol.adi8039.
7
Dynamics of temporal immune responses in nonhuman primates and humans immunized with COVID-19 vaccines.COVID-19 疫苗接种的非人类灵长类动物和人类的时间免疫反应动力学。
PLoS One. 2023 Oct 19;18(10):e0287377. doi: 10.1371/journal.pone.0287377. eCollection 2023.
8
A wild boar cathelicidin peptide derivative inhibits severe acute respiratory syndrome coronavirus-2 and its drifted variants.一种野猪抗菌肽衍生物可抑制严重急性呼吸综合征冠状病毒 2 及其变异株。
Sci Rep. 2023 Sep 5;13(1):14650. doi: 10.1038/s41598-023-41850-7.
9
Anamnestic humoral correlates of immunity across SARS-CoV-2 variants of concern.针对关切的 SARS-CoV-2 变异株的免疫的记忆体液相关性。
mBio. 2023 Aug 31;14(4):e0090223. doi: 10.1128/mbio.00902-23. Epub 2023 Aug 3.
10
Mutational Analysis of Circulating Omicron SARS-CoV-2 Lineages in the Al-Baha Region of Saudi Arabia.沙特阿拉伯巴哈地区循环的奥密克戎SARS-CoV-2谱系的突变分析
J Multidiscip Healthc. 2023 Jul 27;16:2117-2136. doi: 10.2147/JMDH.S419859. eCollection 2023.
本文引用的文献
1
Neutralizing Activity of BNT162b2-Elicited Serum.BNT162b2诱导血清的中和活性
N Engl J Med. 2021 Apr 15;384(15):1466-1468. doi: 10.1056/NEJMc2102017. Epub 2021 Mar 8.
2
Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection.对感染后长达 8 个月的 SARS-CoV-2 进行免疫记忆评估。
Science. 2021 Feb 5;371(6529). doi: 10.1126/science.abf4063. Epub 2021 Jan 6.
3
Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination.SARS-CoV-2 mRNA-1273疫苗接种后反应的持久性。
N Engl J Med. 2021 Jan 7;384(1):80-82. doi: 10.1056/NEJMc2032195. Epub 2020 Dec 3.
4
Development of a Rapid Focus Reduction Neutralization Test Assay for Measuring SARS-CoV-2 Neutralizing Antibodies.用于检测新型冠状病毒2型中和抗体的快速聚焦减少中和试验分析方法的开发
Curr Protoc Immunol. 2020 Dec;131(1):e116. doi: 10.1002/cpim.116.
5
Rapid Generation of Neutralizing Antibody Responses in COVID-19 Patients.新冠病毒肺炎患者中中和抗体反应的快速产生
Cell Rep Med. 2020 Jun 23;1(3):100040. doi: 10.1016/j.xcrm.2020.100040. Epub 2020 Jun 8.
6
An mRNA Vaccine against SARS-CoV-2 - Preliminary Report.mRNA 疫苗对 SARS-CoV-2 的作用-初步报告。
N Engl J Med. 2020 Nov 12;383(20):1920-1931. doi: 10.1056/NEJMoa2022483. Epub 2020 Jul 14.
Zotero 插件